Department of Radiation Oncology, Stanford University, Stanford, CA.
Department of Radiation Oncology, Stanford University, Stanford, CA.; Stanford Cancer Institute, Stanford University, Stanford, CA..
Semin Radiat Oncol. 2024 Apr;34(2):195-206. doi: 10.1016/j.semradonc.2023.12.002.
Due to their rarity and complexity, sarcomas represent a substantial therapeutic challenge. However, the incredible diversity within and across sarcoma subtypes presents an opportunity for personalized care to maximize efficacy and limit toxicity. A deeper understanding of the molecular alterations that drive sarcoma development and treatment response has paved the way for molecular biomarkers to shape sarcoma treatment. Genetic, transcriptomic, and protein biomarkers have become critical tools for diagnosis, prognostication, and treatment selection in patients with sarcomas. In the future, emerging biomarkers like circulating tumor DNA analysis offer the potential to improve early detection, monitoring response to treatment, and identifying mechanisms of resistance to personalize sarcoma treatment. Here, we review the current state of molecular biomarkers for sarcomas and highlight opportunities and challenges for the implementation of new technologies in the future.
由于肉瘤的罕见性和复杂性，它们是治疗的重大挑战。然而，肉瘤亚型内部和之间存在的巨大差异为个性化护理提供了机会，以最大限度地提高疗效并限制毒性。对驱动肉瘤发生和治疗反应的分子改变的深入了解为分子生物标志物塑造肉瘤治疗铺平了道路。遗传、转录组和蛋白质生物标志物已成为肉瘤患者诊断、预后和治疗选择的关键工具。在未来，循环肿瘤 DNA 分析等新兴生物标志物有可能改善早期检测、监测治疗反应以及确定耐药机制，从而实现肉瘤治疗的个体化。在这里，我们回顾了肉瘤的分子生物标志物的现状，并强调了未来实施新技术的机遇和挑战。
